Priorities in Parkinson's disease research
Wassilios G. Meissner(Centre National de la Recherche Scientifique), Erwan Bézard(Centre National de la Recherche Scientifique), David M. Weiner(Ono Pharmaceutical (United States)), Paola Piccini(Imperial College London), Olivier Rascol(Université Toulouse III - Paul Sabatier), Anthony H.V. Schapira(Queen Mary University of London), José Á. Obeso(Universidad San Pablo CEU), Thomas Gasser(German Center for Neurodegenerative Diseases), Andrés M. Lozano(University Health Network), Valerie Voon(University Health Network), Mark Frasier(Michael J. Fox Foundation), François Tison(Institut des Maladies Neurodégénératives), Christopher G. Goetz(Rush University Medical Center)
Cited by 430
Related Papers
Deep Brain Stimulation for Treatment-Resistant Depression
|Neuron|2005|4.1k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease
|Nature reviews. Neuroscience|2010|1.1k
Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
|Biological Psychiatry|2008|1k
Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy
|Human Molecular Genetics|2010|896